Abbott reports fourth-quarter sales that miss analysts’ estimates.

Abbott Laboratories reported Q4 2025 sales of $11.46 billion, an increase of 4.4% from the previous year but falling short of analyst projections by approximately 3%. The adjusted EPS was $1.50, ...

Abbott missed analysts’ profit expectations for Q4 2025, yet the company’s full year financials were buoyed by strong ...

Abbott shares fell after quarterly sales and early 2026 earnings guidance missed estimates, even as the company forecast ...

Abbott shares sank 8% as Q4 revenue of $11.5B missed the $11.8B target, with nutrition sales dropping 8.9% on price ...

Analysts' ratings for Abbott Laboratories (NYSE:ABT) over the last quarter vary from bullish to bearish, as provided by 4 analysts. The following table encapsulates their recent ratings, offering a ...

Abbott Laboratories fell on its latest earnings report, but I view this as a buying opportunity. Read the latest analysis on ...

Abbott Laboratories stock has reached a 52-week low, closing at $107.27. This marks a notable point for the healthcare company, as it navigates a challenging market environment. Over the past year, ...

The medical device maker announced it anticipates first quarter adjusted profits per share between $1.12 and $1.18, trailing ...

Abbott's revenue has been flat over 15 months with steady Q3 EPS of $1.30, 7% growth, and upcoming Q4 international segment ...

This was the stock's fourth consecutive day of losses.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you ...